Summary
Thermo Fisher Scientific Inc. (TMO) reported its first-quarter 2022 financial results, demonstrating robust revenue growth despite a slight decrease in GAAP operating income and EPS compared to the prior year. Total revenues increased by a significant 19% year-over-year to $11.82 billion. This growth was primarily driven by strong performance in the Laboratory Products and Biopharma Services segment, which benefited from the acquisition of PPD, Inc., and solid contributions from Analytical Instruments and Life Sciences Solutions. The company's strategic focus on innovation, emerging markets, and customer value proposition continues to underpin its growth. While GAAP diluted EPS saw a slight decline, adjusted EPS remained strong, highlighting the company's operational efficiency and strategic execution. The company also maintained a strong cash flow, generating $1.56 billion in free cash flow, underscoring its financial health and capacity for future investments and shareholder returns. Looking ahead, Thermo Fisher is navigating a dynamic market environment, including ongoing impacts of the COVID-19 pandemic and inflationary pressures. The company's substantial backlog of remaining performance obligations, amounting to $28.84 billion, with approximately 59% expected to be recognized in the next twelve months, provides a degree of revenue visibility. Management reiterated its confidence in the company's ability to meet its financial obligations and pursue strategic growth initiatives, supported by its strong balance sheet and access to capital.
Financial Highlights
54 data points| Revenue | $11.82B |
| R&D Expenses | $364.00M |
| SG&A Expenses | $2.28B |
| Operating Expenses | $9.00B |
| Operating Income | $2.82B |
| Interest Expense | $136.00M |
| Net Income | $2.22B |
| EPS (Basic) | $5.66 |
| EPS (Diluted) | $5.61 |
| Shares Outstanding (Basic) | 392.00M |
| Shares Outstanding (Diluted) | 395.00M |
Key Highlights
- 1Total revenues surged 19% to $11.82 billion in Q1 2022, compared to $9.91 billion in Q1 2021.
- 2The Laboratory Products and Biopharma Services segment experienced significant growth, up 51% driven by the PPD, Inc. acquisition.
- 3GAAP operating income decreased by 7% to $2.82 billion, while GAAP diluted EPS saw a 5% decline to $5.61.
- 4Adjusted earnings per share (non-GAAP) increased by 1% to $7.25, indicating resilience in core operations.
- 5Free cash flow remained strong at $1.56 billion for the quarter, reflecting robust operational cash generation.
- 6The company has a substantial backlog of $28.84 billion in remaining performance obligations, providing future revenue visibility.
- 7Cash and cash equivalents decreased to $2.75 billion as of April 2, 2022, from $4.48 billion at year-end 2021, reflecting strategic deployment of capital.